171 related articles for article (PubMed ID: 28256961)
1. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
[TBL] [Abstract][Full Text] [Related]
6. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Ying JE; Zhu LM; Liu BX
World J Gastroenterol; 2012 Feb; 18(8):736-45. PubMed ID: 22371633
[TBL] [Abstract][Full Text] [Related]
7. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?
Walker EJ; Ko AH
World J Gastroenterol; 2014 Mar; 20(9):2224-36. PubMed ID: 24605022
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W
J Clin Oncol; 2023 Oct; 41(30):4714-4720. PubMed ID: 37847995
[TBL] [Abstract][Full Text] [Related]
9. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer.
Sgouros J; Maraveyas A
Acta Oncol; 2008; 47(3):337-46. PubMed ID: 17957501
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis.
Liu XY; Pan HN; Yu Y
World J Gastrointest Surg; 2024 Mar; 16(3):921-931. PubMed ID: 38577077
[TBL] [Abstract][Full Text] [Related]
11. Novel agents for advanced pancreatic cancer.
Akinleye A; Iragavarapu C; Furqan M; Cang S; Liu D
Oncotarget; 2015 Nov; 6(37):39521-37. PubMed ID: 26369833
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted approaches for treatment of pancreatic cancer.
Huang ZQ; Saluja AK; Dudeja V; Vickers SM; Buchsbaum DJ
Curr Pharm Des; 2011; 17(21):2221-38. PubMed ID: 21777178
[TBL] [Abstract][Full Text] [Related]
13. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
Hamad AA; Amer BE; Hawas Y; Mabrouk MA; Meshref M
Neurol Sci; 2024 May; 45(5):1861-1873. PubMed ID: 38105307
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for pancreatic cancer.
Philip PA
Gastrointest Cancer Res; 2008 Jul; 2(4 Suppl):S16-9. PubMed ID: 19343141
[TBL] [Abstract][Full Text] [Related]
15. The molecular targets for the diagnosis and treatment of pancreatic cancer.
Strimpakos AS; Syrigos KN; Saif MW
Gut Liver; 2010 Dec; 4(4):433-49. PubMed ID: 21253292
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G; Palmer DH; Greenhalf W; Ghaneh P; Jackson R; Cox T; Evans A; Shaw VE; Wadsley J; Valle JW; Propper D; Wasan H; Falk S; Cunningham D; Coxon F; Ross P; Madhusudan S; Wadd N; Corrie P; Hickish T; Costello E; Campbell F; Rawcliffe C; Neoptolemos JP
Lancet Oncol; 2017 Apr; 18(4):486-499. PubMed ID: 28259610
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Chen J; Xiao-Zhong G; Qi XS
J Immunol Res; 2017; 2017():8282391. PubMed ID: 28265583
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
20. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
